A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
UCB Biopharma SRL
Study ID
NCT04009499
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bimekizumab — DRUG
    Subjects will receive bimekizumab at pre-specified time-points.

Study Details

This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).

Key Dates

Start date
Aug 13, 2019
Status verified
May 2026
Primary completion
May 26, 2026
Completion
May 26, 2026

Study Design

Enrollment
1,131 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekzumab dosage regimen
    Subjects participating in the study will receive assigned bimekizumab dosage regimen during the Treatment Period.

Primary Outcome Measure

Incidence of treatment-emergent adverse events (TEAEs) during the study [ Time Frame: From PA0012 Entry Visit until Safety Follow-Up (up to Week 212) ]

Locations (31)

FacilityCityStateZIPSite coordinators
Pa0012 50017PhoenixArizona85037-
Pa0012 50035San DiegoCalifornia92128-
Pa0012 50033Palm HarborFlorida34684-
Pa0012 50037TampaFlorida33613-
Pa0012 50039AtlantaGeorgia30342-
Pa0012 50024BoiseIdaho83702-
Pa0012 50028LexingtonKentucky40504-
Pa0012 50023Baton RougeLouisiana70836-
Pa0012 50015HagerstownMaryland21740-
Pa0012 50047BostonMassachusetts02115-5817-
Pa0012 50019LansingMichigan48911-
Pa0012 50016St LouisMissouri63141-
Pa0012 50005FreeholdNew Jersey07728-
Pa0012 50029AlbuquerqueNew Mexico87102-
Pa0012 50010BrooklynNew York11201-
Pa0012 50011New YorkNew York10029-
Pa0012 50034RochesterNew York14642-
Pa0012 50125CharlotteNorth Carolina28211-
Pa0012 50031Winston-SalemNorth Carolina27104-
Pa0012 50040VandaliaOhio45377-
Pa0012 50020DuncansvillePennsylvania16635-
Pa0012 50006WyomissingPennsylvania19610-
Pa0012 50008JohnstonRhode Island02919-
Pa0012 50007OrangeburgSouth Carolina29118-
Pa0012 50001JacksonTennessee38305-
Pa0012 50012MemphisTennessee38119-5214-
Pa0012 50002AustinTexas78731-
Pa0012 50049Corpus ChristiTexas78404-
Pa0012 50036MesquiteTexas75150-
Pa0012 50009WacoTexas76710-
Pa0012 50050BeckleyWest Virginia25801-

Related coverage on Hipa.ai

Find similar trials in Phoenix, AZ

By condition
Psoriatic arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
Pa0012 50017· Phoenix, AZPa0012 50035· San Diego, CAPa0012 50033· Palm Harbor, FLPa0012 50037· Tampa, FLPa0012 50039· Atlanta, GAPa0012 50024· Boise, ID

Related Studies